The effectiveness of chemotherapy regimens with the inclusion of linezolid in children and teenagers with tuberculosis
https://doi.org/10.54921/2413-0346-2023-11-4-39-46
Abstract
Purpose. To evaluate the effectiveness of anti-tuberculosis chemotherapy regimens with the inclusion of linezolid in children and teenagers.
Materials and methods. The results of treatment of 55 children and adolescents with tuberculosis when using linezolid in anti-tuberculosis therapy regimens were analyzed. Bacterial excretion was detected in 12.7% of patients at the start of therapy. All children and teenagers included in the study received at least 85% of the daily doses of anti-tuberculosis drugs.
Results. All children and teenagers included in the study showed positive clinical and radiological dynamics at different periods of chemotherapy. Cessation of bacterial excretion was registered in all bacterial isolators by the end of the first month of treatment. The frequency of adverse reactions associated with the use of linezolid was 5.4%; all of them were reversible.
About the Authors
E. D. Zubova
Federal State Autonomous Educational Institution of Higher Education «N.I. Pirogov Russian National Research Medical University» of the Ministry of Health of the Russian Federation;
The Moscow Research and Clinical Center for Tuberculosis Control of the Moscow Government Department of Health
Russian Federation
Russian Federation
Moscow
E. R. Tokhtakhodzhaeva
Federal State Autonomous Educational Institution of Higher Education «N.I. Pirogov Russian National Research Medical University» of the Ministry of Health of the Russian Federation;
The Moscow Research and Clinical Center for Tuberculosis Control of the Moscow Government Department of Health
Russian Federation
Russian Federation
Moscow
O. K. Kiselyevich
Federal State Autonomous Educational Institution of Higher Education «N.I. Pirogov Russian National Research Medical University» of the Ministry of Health of the Russian Federation;
The Moscow Research and Clinical Center for Tuberculosis Control of the Moscow Government Department of Health
Russian Federation
Russian Federation
Moscow
A. N. Yusubova
Federal State Autonomous Educational Institution of Higher Education «N.I. Pirogov Russian National Research Medical University» of the Ministry of Health of the Russian Federation;
The Moscow Research and Clinical Center for Tuberculosis Control of the Moscow Government Department of Health
Russian Federation
Russian Federation
Moscow
References
1. Бердюгина О.В., Ершова А.В. Дифференциальный подход в оценке реакции иммунной системы на присутствие возбудителя туберкулеза с разной лекарственной чувствительностью // Российский иммунологический журнал. – 2017. – Т. 11 (20). – С. 103-106.
2. Борисов С.Е., Филиппов А.В., Иванова Д.А., Иванушкина Т.Н., Литвинова Н.В., Гармаш Ю.Ю. Эффективность и безопасность основанных на использовании бедаквилина режимов химиотерапии у больных туберкулезом органов дыхания: непосредственные и окончательные результаты // Туберкулез и болезни легких. – 2019. – Т. 97. – № 5. – С. 28-40.
3. Глобальная стратегия и цели по профилактике, уходу и контролю туберкулеза после 2015 года / ВОЗ. – 2014.
4. Жукова Е.М., Колпакова Т.А., Мышкова Е.П., Рейхруд Т.А. Опыт применения бедаквилина в комплексном лечении больного туберкулезом легких с широкой лекарственной устойчивостью М. tuberculosis // Туберкулез и болезни легких. – 2016. – Т. 94. – № 10. – С. 62-67.
5. Приказ Минздрава России от 29 декабря 2014 г. № 951 «Об утверждении методических рекомендаций по совершенствованию диагностики и лечения туберкулеза органов дыхания». – М. 2014. – 37 с.
6. Приказ Минздрава РФ от 21 марта 2003 г. № 109 «О совершенствовании противотуберкулезных мероприятий в Российской Федерации» (с изменениями и дополнениями). – Электронный доступ: https://base.garant.ru/4179360/
7. Федеральные клинические рекомендации по диагностике и лечению туберкулеза органов дыхания с множественной и широкой лекарственной устойчивостью возбудителя. – М.– Тверь: ООО «Издательство «Триада», 2014. – 32 с.
8. Филиппов А.В. Эффективность и безопасность режимов химиотерапии туберкулеза, включающих бедаквилин и антибактериальные препараты широкого спектра действия: Автореф. дисс.… канд. мед. наук. – М., 2020. – С. 97.
9. Codecasa L.R., Toumi M., D’Ausilio A. et al. Cost-effectiveness of bedaquiline in MDR end XDR tuberculosis in Italy // J. Market Access Health Policy. – 2017. – Vol. 5, № 1. – 1283105. doi: 10.1080/20016689.2017.1283105.
10. Prieto L.M., Santiago B., Del Rosal T. et al.; Spanish Paediatric TB Research Network (pTBred). Linezolid-containing treatment regimens for tuberculosis in children // Pediatr Infect Dis J. – 2019. – Vol. 38. – № 3. – рр 263-267. doi: 10.1097/INF.0000000000002093.
11. Singh B, Cocker D, Ryan H, Sloan DJ. Linezolid for drug-resistant pulmonary tuberculosis. Cochrane Database Syst Rev. 2019 Mar 20;3(3):CD012836. doi: 10.1002/14651858.CD012836.pub2.9.
12. Sotgiu G., Centis R., D’Ambrosio L., Spanevello A., Migliori G.B. International Group for the study of Linezolid. Linezolid to treat extensively drug-resistant TB: retrospective data are confirmed by experimental evidence // Eur. Respir. J. – 2013. – Vol. 42. – P. 288-290.
13. WHO treatment guidelines for multidrug-resistant tuberculosis 2018 update рre-final text. – Электронный доступ: www.who.int/tb/publications/2018/WHO.2018MDR-TB.Rx. Guidelines. pre.final text.pdf
14. World Health Organization. WHO consolidated guidelines on drug-resistant tuberculosis treatment. WHO/CDS/TB/2019.3. – Geneva: World Health Organization, 2019. Available: http://www.who.int/tb/publications/2019/consolidatedguidelinesdrug-resistant-TBtreatment.
15. Zhang X., Falagas M.E., Vardakas K.Z., Wang R., Qin R., Wang J., Liu Y. Systematic review and meta-analysis of the efficacy and safety of therapy with linezolid containing regimens in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis // J Thorac Dis. – 2015. – Vol. 7. №4. – Р. 603-615. doi: 10.3978/j.issn.2072-1439.2015.03.10.
Review
For citations:
Zubova E.D., Tokhtakhodzhaeva E.R., Kiselyevich O.K., Yusubova A.N. The effectiveness of chemotherapy regimens with the inclusion of linezolid in children and teenagers with tuberculosis. Tuberculosis and socially significant diseases. 2023;11(4):39-46. (In Russ.) https://doi.org/10.54921/2413-0346-2023-11-4-39-46
Views:
65
Email this article 